Sanofi Appoints Belén Garijo as CEO, Vows to Curb $18.4 Bn Dupixent Reliance

Why It Matters

Sanofi’s reliance on a single blockbuster mirrors a broader industry pattern where legacy pharma firms depend heavily on aging biologics. Garijo’s appointment signals a decisive shift toward proactive portfolio management, a move that could set a precedent for other companies facing similar patent cliffs. The outcome will influence investor confidence across the sector and may accelerate M&A activity as peers scramble to secure their own pipelines. Furthermore, the strategic emphasis on defending Dupixent’s patents while simultaneously seeking new assets highlights the delicate balance between short‑term revenue protection and long‑term innovation. How Sanofi navigates this balance will affect not only its own market valuation but also the competitive dynamics of the global immunology market.

Key Takeaways

• Belén Garijo becomes Sanofi CEO on April 29, succeeding Paul Hudson.
• Dupixent generated €15.7 bn ($18.4 bn) in sales last year, up 20%, with a 31% quarterly jump.
• Dupixent’s patent expires in 2031, prompting a strategic push for diversification.
• Sanofi’s M&A budget can support deals up to $30 bn to broaden its pipeline.
• More than 50 patents extend Dupixent protection to 2045, part of the defensive strategy.

Pulse Analysis

Garijo steps into a role that blends crisis management with growth ambition. The immediate priority is to mitigate the revenue shock that a 2031 patent expiry could generate. Historically, pharma firms that successfully navigated similar cliffs—such as Pfizer with Lipitor—leveraged a mix of internal development and strategic acquisitions. Sanofi’s sizable war chest gives it the flexibility to pursue bolt‑on deals, but the market will scrutinize the quality of targets rather than sheer spend.

The broader industry context underscores a shift toward platform‑based biologics, where companies aim to extend product lifecycles through next‑generation formulations and combination therapies. Sanofi’s partnership with Regeneron on Dupixent provides a template for co‑development, yet the firm must avoid over‑reliance on external partners. Garijo’s background in operational leadership suggests she may prioritize internal R&D acceleration, potentially reshaping Sanofi’s innovation pipeline.

Looking ahead, the success of Garijo’s strategy will be measured by the pipeline’s depth by 2028, the pace of M&A closures, and the resilience of Dupixent’s sales amid biosimilar competition. If Sanofi can deliver a diversified revenue mix before the patent cliff, it will reinforce the value of decisive leadership transitions in the pharma sector. Conversely, a failure to replace Dupixent’s earnings could trigger a broader reassessment of how large drugmakers manage legacy assets.